Business Context and Reporting Period
This Form 6-K filing by WORK Medical Technology Group LTD covers the month of April 2026, with the report dated April 15, 2026. The filing discloses corporate governance changes regarding the Board of Directors, specifically the resignation of an independent director and the appointment of a replacement.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the composition of the Board of Directors and its committees:
- Resignation: Mr. Xiaoyang Li resigned as an independent director and member of the Audit, Compensation, and Nominating and Corporate Governance Committees, effective March 23, 2026. He also stepped down as Chairperson of the Compensation Committee. The resignation was due to personal reasons.
- Appointment: Dr. Qisheng Lin was appointed as an independent director to fill the vacancy, effective March 23, 2026. He was appointed to the Audit, Compensation, and Nominating and Corporate Governance Committees and named Chairperson of the Compensation Committee.
Outlook, Risks, and Management Commentary
Management Commentary: The Board determined that Dr. Lin qualifies as an "independent director" under Nasdaq Listing Rule 5605(a)(2). He has no family relationship with other directors or executive officers and has not been involved in reportable transactions with the Company in the past two years.
Background of New Director: Dr. Lin holds a Ph.D. in Medicine from Shanghai Jiao Tong University School of Medicine. His experience includes serving as an Associate Professor in Nephrology at Renji Hospital (since January 2025), a Fellow at the same institution (since July 2024), and an Associate Researcher at the Icahn School of Medicine at Mount Sinai (2019–2021).
Risks and Contingencies: The filing does not disclose new material risks, contingencies, or unusual items beyond the standard disclosure of director changes.
Key Facts for Investor Verification
- Verify the effective date of the Board changes (March 23, 2026) against the company's official corporate records.
- Confirm Dr. Qisheng Lin's independence status and lack of conflicts of interest as stated in the filing.
- Note that this filing is incorporated by reference into the Company's Form F-3 registration statement (File No. 333-289943).
- Recognize that this document contains no financial results; investors should refer to Form 20-F for financial data.